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Abstract
Introduction: It is unclear how to manage high risk hemodialysis patients who present with an
indwelling catheter. The National Kidney Foundation Practice Guidelines urge prompt removal of
the catheter, but the guidelines do not specifically address the problem of patients whose only
option is a femoral arteriovenous (AV) graft.
Methods: This study was a retrospective review of all patients who underwent femoral AV graft
placement for hemodialysis access between January 1, 1996 and January 1, 2003 at the Uni-
versity of Michigan Health System (UMHS). Graft patency is reported according to the standards
developed by the Society of Vascular Surgery and the American Association of Vascular Sur-
geons.
Results: Thirty patients were identified who had undergone femoral AV graft placement. The mean
follow-up was 23 months (range 1–75 months). The patients had had significant medical co-
morbidities and multiple previous access operations (mean 3; interquartile range 1–5). The 1-year
secondary graft patency rate was 41%, the 2-year rate was 26%, and the 3-year rate was 21%.
Infection was the cause of final graft loss in eight patients (50% of the grafts losses, 27% of the
total grafts placed.) Among those who died (n = 14), the mean time from femoral graft placement
to death was 31.2 – 27.5 months. The patient survival was quite low: at 1 year 81%, at 2 years
68%, and at 3 years 54%.
Conclusions: These complex patients who have exhausted their upper extremity hemodialysis
options do poorly following femoral AV graft placement. Consideration should be given to long-
term catheter-based access in some of these patients.
Patients who are no longer candidates for upperextremity hemodialysis arteriovenous (AV) grafts or
fistulas present a difficult problem. These patients usually
have had multiple previous access surgeries, have been
in renal failure for extended periods of time, and have
multiple, severe medical co-morbidities. In our experi-
ence, these patients rarely have peritoneal dialysis or
transplantation as an option. Surgeons generally agree
that upper extremity hemodialysis options are preferred.
There are encouraging reports of good results with fem-
oral AV grafts for hemodialysis,1,2 as well as reports of
relatively poor outcomes with these grafts.3,4
In our experience, these patients are uniquely at high risk
with significant short-term mortality. Luckily, with aggres-
sive measures to find alternatives to femoral access, such
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as angiographic recanalization of central veins, few pa-
tients require femoral AV grafts for hemodialysis access. It
is unclear how to deal with the very high risk patient who
presents with an indwelling catheter. The National Kidney
Foundation Practice Guidelines suggest removing the
catheter in most patients, but the guidelines do not spe-
cifically address femoral AV graft access. For the sake of
improving the care of these complex patients, we report our
experience with femoral AV grafts using the reporting
standards of the Society of Vascular Surgeons and the
American Association of Vascular Surgeons (SVS/AAVS).
METHODS
Patients in this study included adults who underwent
femoral AV graft placement between January 1, 1996 and
January 1, 2003 at the University of Michigan Health
System (UMHS). Permission was obtained from our
institutional human subjects committee. Patients were
identified through review of the medical records. Data
obtained included demographic information (gender and
age), baseline clinical information (type of disease lead-
ing to end-stage renal failure, medical co-morbidities,
number of previous access operations, the reason for
femoral access), data on the access operation (date of
operation, inflow vessel used, outflow vessel used, size of
graft used), and information on the postoperative course
(complications, date and reason for graft failure, number
and efficacy of graft salvage procedures).
Baseline characteristics were compared using Fisher’s
exact test for dichotomous variables and the Wilcoxon
rank-sum test for continuous variables. Primary and sec-
ondary patency is reported according to standards devel-
oped by the SVS/AAVS. Primary graft failure requires an
intervention to reinstate patency at an access site, includ-
ing surgical interventions such as thrombectomy. Final
graft failure precipitates abandoning an access site. Pri-
mary patency continues until primary graft failure. Sec-
ondary patency continues until final graft failure.
Actuarial graft patency and patient survival were
determined using the Kaplan-Meier method. Groups were
compared by the log-rank test. Statistical analysis was
performed using SAS version 8.0 (SAS Institute, Cary,
NC, USA).
RESULTS
Thirty patients were identified who underwent femoral
AV graft placement. The mean follow-up was 23 months
(range 1–75 months). The mean age at the time of
placement was 48 years (range 16–77 years). Altogether,
13 patients were male (43%) and 12 patients (40%) were
African American. A group of 28 (93%) required femoral
AV grafts owing to lack of upper extremity vascular outflow,
1 patient because of lack of upper extremity inflow, and 1
because of inability to control his arm during dialysis.
As expected, the patients had significant medical co-
morbidities (Table 1). The most common cause of renal
failure was diabetes (8 patients, 27% of total). Other
common etiologies of renal failure included hypertension
(3 patients, 10%), congenital nephropathy (3 patients,
10%), obstructive uropathy (3 patients, 10%), chronic
pyelonephritis (2 patients, 7%), medication toxicity (2 pa-
tients, 7%), nephrolithiasis (2 patients, 7%), and hemo-
lytic-uremic syndrome (2 patients, 7%).
The median number for previous access operations
was 3 [interquartile range (IQR) 1–5]. The common
femoral artery was used for inflow in two-thirds of the
cases and the superficial femoral artery in one-third. The
common femoral vein was used for outflow in 16 cases
(55%), the saphenofemoral junction in 9 cases (31%),
and the saphenous vein in 4 cases (14%). The vessels
chosen for the procedure had no significant effect on
thrombosis, infection, or ischemia. Intravenous heparin
was used prior to arterial occlusion. Generally, antiplat-
elet or anticoagulation therapy was resumed only if the
patient had been on it preoperatively or if we documented
a hypercoagulable state.
The perioperative (within 30 days of operation) com-
plications are detailed in Table 2. The most common
perioperative complication was graft thrombosis (n = 5,
17% of patients).
The median time from graft placement to first graft
failure was 81 days (n = 18, IQR 42–196). The 1-year
secondary graft patency rate was 41% (12 patients), the
2-year rate was 26% (9 patients), and the 3-year rate was
21% (6 patients). Actuarial secondary graft patency is





Coronary artery disease 16 (53%)
Obesity (BMI > 40) 15 (50%)
Diabetes 10 (33%)
Deep venous thrombosis 5 (17%)
Hyperlipidemia 4 (13%)
Peripheral vascular disease 3 (10%)
BMI: body mass index.
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final graft failure; or if there was no specific final graft
failure, it was the interval to death (censored event).
Seven patients (23%) underwent one operation/inter-
vention to salvage graft function, four patients (13%)
underwent two salvage operations/interventions, and
three patients (10%) underwent three or more operative
attempts at salvage. Among the patients who had sal-
vage procedures (n = 14), the types of procedures done
are shown in Table 3.
Among the patients with graft failure (primary graft
failure, n = 18; secondary graft failure, n = 16), the
sources of primary and secondary failure, respectively,
were infection (6 patients, 33%; 8 patients, 50%),
thrombosis (10 patients, 56%; 7 patients, 44%), and
ligation (2 patients, 11%; 1 patient, 6%). Infection was the
cause of final graft loss for 27% of the total grafts placed.
Patient survival was quite low: 1 year 81%, 2 years
68%, and 3 years 54%. Actuarial patient survival is shown
in Figure 2. At the conclusion of the study, nine patients
(27%) were alive with a failed graft, and seven patients
(23%) were alive with a functioning graft. Among those
who died (n = 14), the mean time from femoral graft
placement to death was 31.2 – 27.5 months.
DISCUSSION
A modest number of studies on femoral AV grafts for
hemodialysis access have reported a relatively good
outcome for this type of access.5–7 One study reported a
1-year secondary patency rate of 83% with an infection
rate of 22%.1 Another study reported a 1-year secondary
patency rate of 73%, with only 2 of 37 grafts becoming
infected.2 This study concluded that femoral AV grafts
may be preferred to upper extremity AV grafts.
In contrast, there are reports of relatively poor out-
comes with femoral AV grafts. The largest series on
femoral AV grafts for hemodialysis (n = 134) reported a
1-year graft survival rate of 62% (83 patients) with a 46%
infection rate.3 Another series reported a primary patency
rate of only 34% and a secondary patency rate of 68% at
1 year. This series also reported significant infection in
41% of the grafts.4 The authors concluded that femoral
access can provide durable access in selected patients
with few other access options but suggested that a tun-
neled, cuffed catheter should be considered in high risk
patients (morbidly obese patients and those with limited
survival).
It is difficult to compare these retrospective series, as
methods of reporting differ significantly. The patients in
our report had worse outcomes than did those in other
series in the literature. Our secondary patency rate was
only 41% at 1 year, with more than half of the patients
requiring reoperation for graft salvage. These results are
likely attributable to patient selection and referral patterns
to our tertiary center. Publication bias may also have
contributed to our results comparing poorly to those in the
literature. Also, patients who undergo femoral access
surgery at our center have exhausted all other access
options, are usually long-term dialysis patients, and suffer
from many severe medical co-morbidities (Table 1). Al-
most half of the patients had a significant perioperative
surgical complication, with graft thrombosis (5 patients,
17%) being the most common (Table 2). These patients
frequently were morbidly obese, which has been previ-
ously reported to be a risk factor for early access failure.4
It is also interesting that four of our patients (13%) re-
quired postoperative admission to address an urgent
medical issue. The fact that general anesthesia was used
in most of the cases likely contributed to some of these
admissions. Infection (grade 2 infection, SVS/AAVS
reporting standards) was also a significant problem in our
patients, with eight grafts (27%) lost to infection. These
infections were rarely perioperative (n = 2; 7% of all
cases) and presumably were the result of percutaneous
access. Obesity was not noted to be a risk factor for
infection, but definitive conclusions are difficult because
of the small size of the series. We observed, as have














Graft thrombectomy 6 (43%)
Revision 5 (36%)
Lymphocele drainage 3 (21%)
Reexploration 2 (14%)
Hematoma evacuation 1 (7%)
Above-knee amputation 1 (7%)
Lower extremity thrombectomy 1 (7%)
Incision and drainage of an abscess 1 (7%)
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women, presumably because women are smaller and
have more problems with upper extremity venous out-
flow.2–4
The mean time from graft placement to death was less
than 3 years. Although no deaths were directly attribut-
able to complications of access surgery, this is obviously
a high risk group. Similar mortality rates have been re-
ported in other series.4,5
The National Kidney Foundation Guidelines do not fa-
vor catheters for hemodialysis access, stating that fewer
than 10% of chronic hemodialysis patients should be
maintained via catheters.8 The reason for such disfavor is
the poor blood flow through the catheter with resultant
inadequate hemodialysis and an increased rate of sys-
temic infection with the need for hospitalization compared
to AV grafts.9–12 These guidelines are based on com-
parisons between catheters and upper extremity AV
grafts and as a result do not apply to the patients who
present for femoral AV graft placement. For tunneled,
cuffed catheters, the recommended target rate of sys-
temic infection is less than 10% at 3 months and less than
50% at 1 year. Catheter malfunction is common but easily
managed.8
In our experience, it is uncommon that interventional
radiologists are unable to place a cuffed, tunneled internal
jugular or subclavian vein hemodialysis catheter, even in
the most complex patients. If the only option is a femoral
AV graft or a cuffed, tunneled femoral catheter, the AV
graft is generally a better option owing to high rates of
infection in chronic indwelling femoral catheters.13
In many high risk patients (estimated short life expec-
tancy, morbid obesity, severe peripheral vascular occlu-
sive disease), an upper extremity indwelling catheter may
be a better option when the overall operative risks and
outcomes of femoral AV grafts are considered. Unfortu-
nately, we do not have detailed data on the outcomes of a
well matched cohort of patients who underwent hemodi-
alysis via a cuffed catheter.
CONCLUSIONS
Patients who have exhausted their upper extremity
hemodialysis options do poorly and have high compli-
cation rates. Consideration should be given to catheter-
Figure 2. Patient survival.
Figure 1. Secondary graft patency.
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based access in certain high risk patients. A random-
ized multiinstitutional trial is needed to determine spe-
cific groups of patients who would benefit from a
femoral graft rather than a cuffed catheter. We hope
that similar single center reviews can provide the ini-
tiative and background information necessary for such
future investigations.
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